Andrea Worschech
Overview
Explore the profile of Andrea Worschech including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomei S, Mamtani R, Al Ali R, Elkum N, Abdulmalik M, Ismail A, et al.
J Transl Med
. 2015 Apr;
13:119.
PMID: 25890290
Objectives: In Qataris, a population characterized by a small size and a high rate of consanguinity, between two-thirds to three-quarters of adults are overweight or obese. We investigated the relevance...
2.
Lutz M, Worschech A, Alb M, Gahn S, Bernhard L, Schwab M, et al.
Blood
. 2014 Nov;
125(2):261-72.
PMID: 25395422
Donor-derived immunity against tumor-associated antigens (TAAs) may exert selective antileukemic activity reprieving the allogeneic recipient from graft-versus-host disease. As TAAs are highly expressed in placental tissues we hypothesized that pregnancy...
3.
Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, et al.
Mol Oncol
. 2014 Sep;
9(1):93-104.
PMID: 25174651
Background: The existence of a dichotomy between immunologically active and quiescent tumor phenotypes has been recently recognized in several types of cancer. The activation of a Th1 type of immune...
4.
De Giorgi V, Buonaguro L, Worschech A, Tornesello M, Izzo F, Marincola F, et al.
PLoS One
. 2013 Feb;
8(2):e56153.
PMID: 23441164
Unlabelled: Hepatocellular carcinomas (HCCs) are a heterogeneous group of tumors that differ in risk factors and genetic alterations. In Italy, particularly Southern Italy, chronic hepatitis C virus (HCV) infection represents...
5.
Reinboth J, Ascierto M, Chen N, Zhang Q, Yu Y, Aguilar R, et al.
Hum Gene Ther Methods
. 2012 Nov;
23(5):285-96.
PMID: 23131031
Vaccinia virus (VACV) has emerged as an attractive tool in oncolytic virotherapy. VACV replication efficiency plays a crucial role in the therapeutic outcome. However, little is known about the influence...
6.
Xie Q, Bradley R, Kang L, Koeman J, Ascierto M, Worschech A, et al.
Proc Natl Acad Sci U S A
. 2011 Dec;
109(2):570-5.
PMID: 22203985
Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups...
7.
Ascierto M, Worschech A, Yu Z, Adams S, Reinboth J, Chen N, et al.
BMC Cancer
. 2011 Oct;
11:451.
PMID: 22011439
Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we...
8.
Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto M, Wang E, et al.
J Transl Med
. 2011 Oct;
9:170.
PMID: 21978632
Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old)...
9.
Weibel S, Raab V, Yu Y, Worschech A, Wang E, Marincola F, et al.
BMC Cancer
. 2011 Feb;
11:68.
PMID: 21320309
Background: In principle, the elimination of malignancies by oncolytic virotherapy could proceed by different mechanisms--e.g. tumor cell specific oncolysis, destruction of the tumor vasculature or an anti-tumoral immunological response. In...
10.
Slezak S, Worschech A, Wang E, Stroncek D, Marincola F
Adv Exp Med Biol
. 2010 Aug;
684:178-88.
PMID: 20795549
Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means ofeliciting tumor-specific immune responses to mediate...